Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Keratosis, Actinic

Keratosis

Exanthema

Skin Diseases

Precancerous Conditions

0.0025% PEP005 Topical Gel (Day 1,2 application)

PEP005

0.01% PEP005 Topical Gel (Day 1,2 application)

0.05% PEP005 Topical Gel (Day 1,2 application)

0.0025% PEP005 Topical Gel (Day 1,8 application)

0.01% PEP005 Topical Gel (Day 1,8 application)

0.05% PEP005 Topical Gel (Day 1,8 application)

Greg Siller

The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of actinic keratoses.

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses

A Multi-center, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Actinic Keratoses

Peplin

Janelle Katsamas

Lawrence Anderson, Dr

Peter Welburn, PhD

Actinic keratoses (AK) is a common skin condition characterized by rough, scaly patches or sores on the top layer of the skin which if left untreated can progress to skin cancer. Current treatments can cause scarring and hypopigmentation, be inconvenient, or require long treatment duration. Non-invasive alternative therapy for treatment of AK lesions is thus being researched.

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.

Lawrence Anderson, MD, F.A.C.P

The purpose of this study is :

* To determine the maximum tolerated dose (MTD) for PEP005 Topical Gel in patients with actinic keratoses.
* To evaluate patients for clinical safety
* To determine the systemic absorption of PEP005 Topical Gel

Actinic keratoses (AK) is a common skin condition characterized by rough, scaly patches or sores on the top layer of the skin which if left untreated can progress to skin cancer. Current treatments can cause scarring and hypopigmentation, be inconvenient, or require long treatment duration. Non-invasive alternative therapy for treatment of AK lesions is thus being researched.

This is an open label, dose escalation, cohort study to determine the maximum tolerated dose (MTD) of PEP005 Topical Gel, administered once daily for two consecutive days (90 ul gel applied topically over a 3 x 3cm template surrounding a target lesion), to patients with actinic keratoses (AK). The study will be conducted in one centre in the US. Three patients will be entered initially at the lowest dose level (0.01%) with up to an additional three patients to be entered in the event of a dose limiting toxicity (DLT) in the initial patients. DLT are defined as 'severe' local skin reactions observed by the Investigator, either prior to treatment on Day 2 ( following treatment on Day 1 ) or observed on Day 8 (following treatment on Day 2). Based on findings from phase I studies and the low systemic absorption found in non-clinical toxicokinetic evaluations, no systemic toxicity is anticipated.Once determined A total of 10 patients will be treated at the MTD in order to confirm it's determination. Based on findings from the phase I study, the starting dose will be 0.01% PEP005 Gel.

Secondary objectives of the study are (1) evaluate the clinical efficiency of PEP005 Topical Gel, when administered once daily for two consecutive days and (2) determine the systemic absorption of PEP005 Topical Gel at the MTD . Hematologic and biochemical assessments will be undertaken at the screening visit and at days 8 and 29 . Adverse events will be assessed at every study visit. Clinical response to treatment will be assessed at Days 8, 15 and 29.

Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel

An Open-label, Dose Escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel When Applied on Day 1 and Day 2 to Actinic Keratoses on the Shoulders, Chest, Back or Arms Followed by a Post-Treatment Follow-up Period Lasting at Four Weeks

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses	NCT00107965	Actinic Keratos...	PEP005 PEP005 PEP005 PEP005 PEP005 PEP005 PEP005 PEP005	18 Years -	Peplin
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses	NCT00375739	Actinic Keratos...	PEP005	18 Years -	Peplin
Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel	NCT00239135	Keratosis	PEP005	18 Years -	Peplin
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses	NCT00375739	Actinic Keratos...	PEP005	18 Years -	Peplin

Spots Global Cancer Trial Database for sun spots

Every month we try and update this database with for sun spots cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for sun spots

Every month we try and update this database with for sun spots cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for sun spots cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.